Taxotere docetaxel data

RPR presented preliminary Phase II data at the European Congress for Clinical Oncology in Paris, showing a 42 percent response rate (13 of 30 evaluable patients with metastatic disease) and median duration of response of five months. One patient had a complete response for more than 14 months.

Patients received a 100 mg/m2 dose as a one-hour infusion every three weeks. ...